Now showing items 1-7 of 7

    • Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. 

      Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; Yuan, W; Athie, A; Casals, T; Carmichael, J; Rodrigues, DN; Gurel, B; Rescigno, P; Rekowski, J; Welti, J; Riisnaes, R; Gil, V; Ning, J; Wagner, V; Casanova-Salas, I; Cordoba, S; Castro, N; Fenor de la Maza, MD; Seed, G; Chandran, K; Ferreira, A; Figueiredo, I; Bertan, C; Bianchini, D; Aversa, C; Paschalis, A; Gonzalez, M; Morales-Barrera, R; Suarez, C; Carles, J; Swain, A; Sharp, A; Gil, J; Serra, V; Lord, C; Carreira, S; Mateo, J; de Bono, JS (2020-11-08)
      Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond.Objective To characterise ATM-deficient ...
    • Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. 

      Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; Hamilton, MP; Chrysostomou, SL; Sharp, A; Welti, J; Yuan, W; Dart, DA; Knight, E; Ning, J; Francis, JC; Kounatidou, EE; Gaughan, L; Swain, A; Lupold, SE; de Bono, JS; McGuire, SE; Gidrol, X; Bevan, CL (2019-07)
      Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ...
    • CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. 

      Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; Woolston, A; Spain, G; von Loga, K; Challoner, B; Patel, R; Ranes, M; Swain, A; Thomas, J; Bryant, A; Saffery, C; Fotiadis, N; Guettler, S; Mansfield, D; Melcher, A; Powles, T; Rao, S; Watkins, D; Chau, I; Matthews, N; Wallberg, F; Starling, N; Cunningham, D; Gerlinger, M (2019-04-15)
      Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high levels ...
    • CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. 

      Shenoy, TR; Boysen, G; Wang, MY; Xu, QZ; Guo, W; Koh, FM; Wang, C; Zhang, LZ; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, DN; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, DY; de Bono, J; Wu, H (2017-07)
      Background Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized ...
    • High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. 

      Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; Peckitt, C; Kilgour, E; Smith, NR; Geh, C; Rooney, C; Cutts, R; Campbell, J; Ning, J; Fenwick, K; Swain, A; Brown, G; Chua, S; Thomas, A; Johnston, SRD; Ajaz, M; Sumpter, K; Gillbanks, A; Watkins, D; Chau, I; Popat, S; Cunningham, D; Turner, NC (2016-08)
      Unlabelled FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level ...
    • <i>SOX9</i> is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. 

      Francis, JC; Capper, A; Ning, J; Knight, E; de Bono, J; Swain, A (2018-01-10)
      Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development ...
    • Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). 

      Welti, J; Sharp, A; Yuan, W; Dolling, D; Nava Rodrigues, D; Figueiredo, I; Gil, V; Neeb, A; Clarke, M; Seed, G; Crespo, M; Sumanasuriya, S; Ning, J; Knight, E; Francis, JC; Hughes, A; Halsey, WS; Paschalis, A; Mani, RS; Raj, GV; Plymate, SR; Carreira, S; Boysen, G; Chinnaiyan, AM; Swain, A; de Bono, JS; International SU2C/PCF Prostate Cancer Dream Team (2018-07)
      <b>Purpose:</b> Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently ...